Through research with our community and partners, we have taken big steps in working towards better treatment options for people living with asthma. Our study, “Severe Asthma: The Canadian Patient Journey,” revealed the social, financial and health impacts of Severe Asthma (SA) on the lives of Canadians. We used this landmark study to educate, raise awareness and advocate for the estimated 150,000 – 250,000 Canadians living with SA.

We also worked with Teva Canada in a study of the patterns, causes and effects of eosinophilic asthma to better understand the size and scale of the Severe Asthma community. We are proud to have been a part of this study, which leads to a better understanding of eosinophils, a biomarker found in the blood and it’s relation to asthma, which may lead to the development of more personalized treatments.

Severe Asthma: The Canadian Patient Journey

Our study, Severe Asthma: The Canadian Patient Journey revealed the social, financial and health impacts of Severe Asthma on the lives of Canadians. This landmark study is now used to educate, raise awareness and advocate on behalf of the estimated 150,000 – 250,000 Canadians living with Severe Asthma.

Read the report:

English
Full Report | Executive Summary
French
Full Report | Executive Summary

Characteristics of Patients with Mild to Severe Asthma in Canada

We support collaboration with community and corporate partners on research that furthers treatment options. In 2016 we worked with Teva Canada in an epidemiological study of the patterns, causes and effects of eosinophilic asthma to better understand the size and scale of the Severe Asthma community. We are proud to have been a part of this study, which leads to a better understanding of eosinophils, a biomarker found in the blood and its relation to asthma, which may lead to the development of more personalized treatments.

Read the report here.